Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells

Oncogene

Volumn 33, Issue 12, 2014, Pages 1601-1608

  Masciarelli, S ^a   Fontemaggi, G ^a   Di Agostino, S ^a   Donzelli, S ^a   Carcarino, E ^a   Strano, S ^a   Blandino, G ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemoresistance; Gain of function; MiR 223; Mutant p53; Stathmin 1

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA 223; PONASTERONE A; PROTEIN P53; STATHMIN; TRANSCRIPTION FACTOR ZEB1;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLONOGENESIS; COLON CANCER; DNA DAMAGE; DNA SEQUENCE; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GAIN OF FUNCTION MUTATION; HUMAN; MUTANT; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; REGULATORY MECHANISM; REGULATORY SEQUENCE; TRANSCRIPTION INITIATION SITE; TUMOR CELL; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MUTATION; STATHMIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897069469     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.106     Document Type: Article

References (58)

1. Hainaut P, Hollstein M. P53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 81-137.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science (New York, NY) 1991; 253: 49-53.
3. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev 2009; 9: 701-713.
4. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003; 10: 431-442.
5. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
6. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH et al. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 2001; 276: 39359-39367.
7. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811-814.
8. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995; 1: 1029-1034.
9. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477-485.
10. Lu C, El-Deiry WS. Targeting p53 for enhanced radio-and chemo-sensitivity. Apoptosis 2009; 14: 597-606.
11. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R et al. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998; 16: 3269-3277.
12. Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D et al. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J 2001; 20: 4163-4172.
13. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 2002; 277: 18817-18826.
14. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 2000; 275: 29503-29512.
15. Chicas A, Molina P, Bargonetti J. Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochem Biophys Res Commun 2000; 279: 383-390.
16. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006; 10: 191-202.
17. Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 2009; 16: 1086-1093.
18. Gohler T, Jager S, Warnecke G, Yasuda H, Kim E, Deppert W. Mutant p53 proteins bind DNA in a DNA structure-selective mode. Nucleic Acids Res 2005; 33: 1087-1100.
19. Israel A, Sharan R, Ruppin E, Galun E. Increased microRNA activity in human cancers. PLoS One 2009; 4: e6045.
20. Wang L, Wang J. MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. Oncogene 2011; 31: 2499-2511.
21. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2011; 19: 1038-1048.
22. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev 2006; 6: 857-866.
23. Fukao T, Fukuda Y, Kiga K, Sharif J, Hino K, Enomoto Y et al. An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell 2007; 129: 617-631.
24. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005; 123: 819-831.
25. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820-5828.
26. Haddad Y, Choi W, McConkey DJ. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res 2009; 15: 532-542.
27. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007; 14: 3629-3637.
28. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006; 66: 944-950.
29. Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G et al. The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. Mol Cell Biol 2001; 21: 8461-8470.
30. Mueller PR, Coleman TR, Kumagai A, Dunphy WG. Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science (New York) 1995; 270: 86-90.
31. Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Muller-Tidow C, Bohlander SK et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood 2010; 115: 1768-1778.
32. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 2008; 7: 35.
33. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007; 25: 387-392.
34. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008; 135: 257-269.
35. Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao QL et al. MiR-223 suppresses cell proliferation by targeting IGF-1R. PLoS One 2011; 6: e27008.
36. Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle. J Cell Biochem 2004; 93: 242-250.
37. Melhem RF, Strahler JR, Hailat N, Zhu XX, Hanash SM. Involvement of OP18 in cell proliferation. Biochem Biophys Res Commun 1991; 179: 1649-1655.
38. Johnsen JI, Aurelio ON, Kwaja Z, Jorgensen GE, Pellegata NS, Plattner R et al. P53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer 2000; 88: 685-691.
39. Mistry SJ, Li HC, Atweh GF. Role for protein phosphatases in the cell-cycle-regulated phosphorylation of stathmin. Biochem J 1998; 334(Part 1): 23-29.
40. Bane AL, Pinnaduwage D, Colby S, Reedijk M, Egan SE, Bull SB et al. Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat 2009; 117: 183-191.
41. Cheng AL, Huang WG, Chen ZC, Peng F, Zhang PF, Li MY et al. Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res 2008; 14: 435-445.
42. Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, Brunner N et al. The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 2008; 110: 317-326.
43. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 2009; 106: 4834-4839.
44. Zheng P, Liu YX, Chen L, Liu XH, Xiao ZQ, Zhao L et al. Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res 2010; 9: 4897-4905.
45. Belletti B, Baldassarre G. Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Therap Targets 2011; 15: 1249-1266.
46. Phadke AP, Jay CM, Wang Z, Chen S, Liu S, Haddock C et al. In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein. DNA Cell Biol 2011; 30: 715-726.
47. Rana S, Maples PB, Senzer N, Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008; 8: 1461-1470.
48. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 1999; 18: 5954-5958.
49. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999; 13: 2490-2501.
50. Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 2002; 62: 6864-6869.
51. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007; 26: 1003-1012.
52. Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology (Baltimore, MD) 2007; 46: 759-768.
53. Kang W, Tong JH, Chan AW, Lung RW, Chau SL, Wong QW et al. Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One 2012; 7: e33919.
54. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P et al. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005; 7: 51-63.
55. Manceau V, Gavet O, Curmi P, Sobel A. Stathmin interaction with HSC70 family proteins. Electrophoresis 1999; 20: 409-417.
56. Maucuer A, Camonis JH, Sobel A. Stathmin interaction with a putative kinase and coiled-coil-forming protein domains. Proc Natl Acad Sci USA 1995; 92: 3100-3104.
57. Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V et al. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol 2006; 172: 245-257.
58. Jiang H, Schiffer E, Song Z, Wang J, Zurbig P, Thedieck K et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci USA 2008; 105: 11299-11304.